Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate
There is little published information on effective treatment of Kaposi's sarcoma (KS) in children in low-income countries. We prospectively treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), bleomycin and vinc...
Gespeichert in:
| Veröffentlicht in: | South African medical journal 2017-11, Vol.107 (11), p.952 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | 952 |
| container_title | South African medical journal |
| container_volume | 107 |
| creator | Wharin, P Katayi, E Hesseling, P.B Bardin, R Palmer, D Glenn, M Kruger, M Kouya, F |
| description | There is little published information on effective treatment of Kaposi's sarcoma (KS) in children in low-income countries. We prospectively treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), bleomycin and vincristine sulphate (ABV), with highly active antiretroviral therapy (HAART) plus co-trimoxazole prophylaxis for those who were HIV-positive, with additional vincristine if remission was not achieved after 4 months. Maintenance HAART plus co-trimoxazole was given to all HIV-positive patients. A fine-needle aspirate and CD4+ count were done if possible, and staging was performed according to Mitsuyasu. Eight of ten HIV-positive patients with stage III-IVB disease, and both HIV-negative patients with stage I disease, were in remission after 473-1 490 (mean 939) days. One patient died after absconding during treatment, and one died from neutropenia-related pulmonary infection. ABV with or without HAART is an effective treatment option for children with KS. S Afr Med J 2017; 107(11):952-953. DOI: 10.7196/SAMJ.2017.v107i11.12559 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_healthsolutions_A513194381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A513194381</galeid><sourcerecordid>A513194381</sourcerecordid><originalsourceid>FETCH-gale_healthsolutions_A5131943813</originalsourceid><addsrcrecordid>eNqNirsOgjAUQDtoIj7-4U66SCJCUdyM8ZE46k4KVFtTegm39fH3MvgBTuec5PRYsFjyNMz4KhmwIdFj0TXP0oBdzqJB0jMCEm2JtdjAEbEC9K4rCS_tFFT4xtYXutR2DoWRWH86BWEreGpbtpqcthLIm0YJJ8esfxOG5OTHEZse9tfdKbwLI3MlhXGK0Hin0VK-5VEcZUm8juK_xy-ArkI4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>African Journals Online (Open Access)</source><source>Sabinet African Journals Open Access Collection</source><source>Alma/SFX Local Collection</source><creator>Wharin, P ; Katayi, E ; Hesseling, P.B ; Bardin, R ; Palmer, D ; Glenn, M ; Kruger, M ; Kouya, F</creator><creatorcontrib>Wharin, P ; Katayi, E ; Hesseling, P.B ; Bardin, R ; Palmer, D ; Glenn, M ; Kruger, M ; Kouya, F</creatorcontrib><description>There is little published information on effective treatment of Kaposi's sarcoma (KS) in children in low-income countries. We prospectively treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), bleomycin and vincristine sulphate (ABV), with highly active antiretroviral therapy (HAART) plus co-trimoxazole prophylaxis for those who were HIV-positive, with additional vincristine if remission was not achieved after 4 months. Maintenance HAART plus co-trimoxazole was given to all HIV-positive patients. A fine-needle aspirate and CD4+ count were done if possible, and staging was performed according to Mitsuyasu. Eight of ten HIV-positive patients with stage III-IVB disease, and both HIV-negative patients with stage I disease, were in remission after 473-1 490 (mean 939) days. One patient died after absconding during treatment, and one died from neutropenia-related pulmonary infection. ABV with or without HAART is an effective treatment option for children with KS. S Afr Med J 2017; 107(11):952-953. DOI: 10.7196/SAMJ.2017.v107i11.12559</description><identifier>ISSN: 0256-9574</identifier><language>eng</language><publisher>Health & Medical Publishing Group</publisher><subject>Bleomycin ; Care and treatment ; Chemotherapy ; Complications and side effects ; Dosage and administration ; Doxorubicin ; Highly active antiretroviral therapy ; Patient outcomes ; Sarcoma</subject><ispartof>South African medical journal, 2017-11, Vol.107 (11), p.952</ispartof><rights>COPYRIGHT 2017 Health & Medical Publishing Group</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Wharin, P</creatorcontrib><creatorcontrib>Katayi, E</creatorcontrib><creatorcontrib>Hesseling, P.B</creatorcontrib><creatorcontrib>Bardin, R</creatorcontrib><creatorcontrib>Palmer, D</creatorcontrib><creatorcontrib>Glenn, M</creatorcontrib><creatorcontrib>Kruger, M</creatorcontrib><creatorcontrib>Kouya, F</creatorcontrib><title>Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate</title><title>South African medical journal</title><description>There is little published information on effective treatment of Kaposi's sarcoma (KS) in children in low-income countries. We prospectively treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), bleomycin and vincristine sulphate (ABV), with highly active antiretroviral therapy (HAART) plus co-trimoxazole prophylaxis for those who were HIV-positive, with additional vincristine if remission was not achieved after 4 months. Maintenance HAART plus co-trimoxazole was given to all HIV-positive patients. A fine-needle aspirate and CD4+ count were done if possible, and staging was performed according to Mitsuyasu. Eight of ten HIV-positive patients with stage III-IVB disease, and both HIV-negative patients with stage I disease, were in remission after 473-1 490 (mean 939) days. One patient died after absconding during treatment, and one died from neutropenia-related pulmonary infection. ABV with or without HAART is an effective treatment option for children with KS. S Afr Med J 2017; 107(11):952-953. DOI: 10.7196/SAMJ.2017.v107i11.12559</description><subject>Bleomycin</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Complications and side effects</subject><subject>Dosage and administration</subject><subject>Doxorubicin</subject><subject>Highly active antiretroviral therapy</subject><subject>Patient outcomes</subject><subject>Sarcoma</subject><issn>0256-9574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqNirsOgjAUQDtoIj7-4U66SCJCUdyM8ZE46k4KVFtTegm39fH3MvgBTuec5PRYsFjyNMz4KhmwIdFj0TXP0oBdzqJB0jMCEm2JtdjAEbEC9K4rCS_tFFT4xtYXutR2DoWRWH86BWEreGpbtpqcthLIm0YJJ8esfxOG5OTHEZse9tfdKbwLI3MlhXGK0Hin0VK-5VEcZUm8juK_xy-ArkI4</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Wharin, P</creator><creator>Katayi, E</creator><creator>Hesseling, P.B</creator><creator>Bardin, R</creator><creator>Palmer, D</creator><creator>Glenn, M</creator><creator>Kruger, M</creator><creator>Kouya, F</creator><general>Health & Medical Publishing Group</general><scope/></search><sort><creationdate>20171101</creationdate><title>Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate</title><author>Wharin, P ; Katayi, E ; Hesseling, P.B ; Bardin, R ; Palmer, D ; Glenn, M ; Kruger, M ; Kouya, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_healthsolutions_A5131943813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Bleomycin</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Complications and side effects</topic><topic>Dosage and administration</topic><topic>Doxorubicin</topic><topic>Highly active antiretroviral therapy</topic><topic>Patient outcomes</topic><topic>Sarcoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wharin, P</creatorcontrib><creatorcontrib>Katayi, E</creatorcontrib><creatorcontrib>Hesseling, P.B</creatorcontrib><creatorcontrib>Bardin, R</creatorcontrib><creatorcontrib>Palmer, D</creatorcontrib><creatorcontrib>Glenn, M</creatorcontrib><creatorcontrib>Kruger, M</creatorcontrib><creatorcontrib>Kouya, F</creatorcontrib><jtitle>South African medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wharin, P</au><au>Katayi, E</au><au>Hesseling, P.B</au><au>Bardin, R</au><au>Palmer, D</au><au>Glenn, M</au><au>Kruger, M</au><au>Kouya, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate</atitle><jtitle>South African medical journal</jtitle><date>2017-11-01</date><risdate>2017</risdate><volume>107</volume><issue>11</issue><spage>952</spage><pages>952-</pages><issn>0256-9574</issn><abstract>There is little published information on effective treatment of Kaposi's sarcoma (KS) in children in low-income countries. We prospectively treated 12 patients with an institutional review board-approved protocol consisting of four monthly courses of doxorubicin (Adriamycin), bleomycin and vincristine sulphate (ABV), with highly active antiretroviral therapy (HAART) plus co-trimoxazole prophylaxis for those who were HIV-positive, with additional vincristine if remission was not achieved after 4 months. Maintenance HAART plus co-trimoxazole was given to all HIV-positive patients. A fine-needle aspirate and CD4+ count were done if possible, and staging was performed according to Mitsuyasu. Eight of ten HIV-positive patients with stage III-IVB disease, and both HIV-negative patients with stage I disease, were in remission after 473-1 490 (mean 939) days. One patient died after absconding during treatment, and one died from neutropenia-related pulmonary infection. ABV with or without HAART is an effective treatment option for children with KS. S Afr Med J 2017; 107(11):952-953. DOI: 10.7196/SAMJ.2017.v107i11.12559</abstract><pub>Health & Medical Publishing Group</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0256-9574 |
| ispartof | South African medical journal, 2017-11, Vol.107 (11), p.952 |
| issn | 0256-9574 |
| language | eng |
| recordid | cdi_gale_healthsolutions_A513194381 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; African Journals Online (Open Access); Sabinet African Journals Open Access Collection; Alma/SFX Local Collection |
| subjects | Bleomycin Care and treatment Chemotherapy Complications and side effects Dosage and administration Doxorubicin Highly active antiretroviral therapy Patient outcomes Sarcoma |
| title | Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A00%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Kaposi's%20sarcoma:%20Good%20outcome%20with%20doxorubicin,%20bleomycin%20and%20vincristine%20sulphate&rft.jtitle=South%20African%20medical%20journal&rft.au=Wharin,%20P&rft.date=2017-11-01&rft.volume=107&rft.issue=11&rft.spage=952&rft.pages=952-&rft.issn=0256-9574&rft_id=info:doi/&rft_dat=%3Cgale%3EA513194381%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A513194381&rfr_iscdi=true |